Whitepaper: Measuring Certainty In The Specialty Pharmaceutical Supply Chain

By Alex Guite; Ruediger Lomb

How Different Non-Excursion Rates Affect Performance

Like most industries, the pharmaceutical market has changed dramatically over the last few decades. The focus on highly profitable blockbuster drugs has been extended to include products targeted at smaller patient populations, including cell and gene therapies. Driving this is a determination from healthcare experts to find cures for diseases affecting millions across the world.

In this whitepaper, you'll learn:

  • How shifts in the industry are leading to more patient-centric healthcare practices
  • The difference between a 99.0% and 99.9% excursion rate
  • How today's pharmaceutical environment has become increasingly complex

Access the whitepaper now to better identify the challenges in the Specialty Pharmaceutical Supply chain in relation to your organization.


About the Authors

Alex Guite

Vice President, Services and Alliances
World Courier
View Bio

Ruediger Lomb

Vice President, Enterprise Quality Assurance, International Operations
AmerisourceBergen Global Commercialization Services & Animal Health
View Bio